Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 576 to 600 of 797

TitleReference numberPublishedLast updated
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA394
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanomaTA396
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetesTA390
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fractionTA388
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancerTA389
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosisTA386
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)TA23
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemiaTA385
Nivolumab for treating advanced (unresectable or metastatic) melanomaTA384

Results per page

  1. 10
  2. 25
  3. 50
  4. All